PubMed Health’s curated collection of systematic reviews now has an important new role: enabling PubMed users to go straight from a clinical trial to systematic reviews that have considered it. Visitors to records of many thousands of trials will now see a new section to the right, called a portlet. It will show links to systematic reviews in PubMed that have cited that trial. This new portlet does not replace “Related citations in PubMed”: that will follow as usual. All of PubMed Health’s 31,100 systematic reviews since 2003 are not yet included. If there is no portlet showing, it does not mean for certain that there is no systematic review that includes the trial. There are enough reviews included, though, that this portlet should become a familiar sight when using PubMed. For additional information, visit the latest issue of the NLM Technical Bulletin.
Archive for the ‘Clinical Trials’ Category
The Coalition for Networked Information (CNI), the Association of Research Libraries (ARL), and EDUCAUSE have announced that Donald A.B. Lindberg, Director of the National Library of Medicine, has been named the 2014 recipient of the Paul Evan Peters Award. The award recognizes notable, lasting achievements in the creation and innovative use of network-based information resources and services that advance scholarship and intellectual productivity. Named for CNI’s founding director, the award honors the memory and accomplishments of Paul Evan Peters (1947–1996), a visionary and a coalition builder in higher education and the world of scholarly communication, who led CNI from its founding in 1990. The award will be presented during the CNI membership meeting in St. Louis, MO, to be held March 31–April 1, 2014, where Dr. Lindberg will deliver the Paul Evan Peters Memorial Lecture. The talk will be recorded and made available on CNI’s YouTube and Vimeo channels after the meeting concludes.
Dr. Lindberg’s interest in the potential intersection between information technology and the biological sciences stretches back to the early days of his career. He joined the pathology faculty at the University of Missouri in 1960, where he developed the first automated lab system and an automated patient history acquisition system. He implemented an automated statewide system for interpreting electrocardiograms, as well as other medical applications for the computer. Around this time, he also began publishing articles in a field that would come to be known as medical informatics, including The Computer and Medical Care, which appeared in 1968.
Dr. Lindberg has worked as a scientist for over 50 years, becoming widely recognized as an innovator in applying computer technology to health care, medical diagnosis, artificial intelligence, and educational programs. In 1984 he was appointed director of the National Library of Medicine (NLM), the world’s largest biomedical library, a post that he still holds. As NLM’s Director, Dr. Lindberg convinced the United States Congress that the Library was an essential information conduit, facilitating the decision-making process of scientists and pharmaceutical companies, and, ultimately, benefiting patients and the general public, thereby securing the organization’s robust future. He has spearheaded countless transformative programs in medical informatics, including the Unified Medical Language System, making it possible to link health information, medical terms, drug names and billing codes across different computer systems; the Visible Human Project, a digital image library of complete, anatomically detailed, three-dimensional representations of the normal male and female human bodies; the production and implementation of ClinicalTrials.gov, a registry and results database of publicly and privately supported clinical studies of human participants conducted around the world; and, the establishment of the National Center for Biotechnology Information, a national resource for molecular biology information and genetic processes that control health and disease. Today, NLM has a budget of $327 million, more than 800 employees, and digital information services that are used billions of times a year by millions of scientists, health professionals, and members of the public.
Dr. Lindberg is a member of the Institute of Medicine of the National Academy of Sciences, and has received numerous honors and awards, including the prestigious Morris F. Collen, MD, Award of Excellence of the American College of Medical Informatics, and the Surgeon General’s Medallion of the US Public Health Service. He received his medical degree from the College of Physicians and Surgeons, Columbia University, and an undergraduate degree from Amherst College. A four-member committee selected Dr. Lindberg for the award: the late Ann J. Wolpert, director of libraries at the Massachusetts Institute of Technology; George O. Strawn, director of the Federal Networking and Information Technology Research and Development (NITRD) National Coordination Office (NCO); Sally Jackson, professor of communication at the University of Illinois at Urbana-Champaign; and Joan Lippincott, associate executive director of the Coalition for Networked Information.
Research funded by the National Library of Medicine provides new insight into why patients stop taking drugs that lower their cholesterol, and what happens when patients try those drugs, known as statins, a second time. Researchers found that more than 90% of patients who stopped taking statins because of an adverse reaction could tolerate the medication when tried again. The study is published in the April 2, 2013, issue of the Annals of Internal Medicine.
NLM grantee Alexander Turchin MD, MS, of Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, notes that statins are commonly stopped even though their benefits are well documented. He and colleagues wanted to better understand why statins are discontinued and whether adverse reactions play a role. They conducted a retrospective study, analyzing clinical data in an electronic medical record (EMR) system. Researchers examined structured data as well as the narrative electronic notes of health providers. Those notes frequently are the only place in an EMR where adverse reactions to medications are documented. Using the NLM grant, researchers developed natural language processing software and scoured more than 5 million notes, on more than 107,000 patients, recorded over nearly a decade. The software generated data on a scale that could not have been done manually. Researchers say the next step would be to conduct a clinical trial to determine if outcomes are improved when statins are tried again, after an adverse event.
The National Library of Medicine, part of the National Institutes of Health, conducts and funds research in biomedical informatics, which involves applying computers and communications technology to the field of health. This research was supported by NLM’s Division of Extramural Programs grant RC1-LM010460. This was an NIH Challenge Grant, supported by NLM with funds from the American Recovery and Reinvestment Act. For additional information, visit the Brigham and Women’s Hospital News Release.
Check out the November issue of NIH News in Health, the monthly newsletter bringing you practical health news and tips based on the latest NIH research. In this edition:
Your Microbes and You: The Good, Bad and Ugly
Trillions of microscopic creatures—like bacteria, fungi and viruses—are living in and on your body right now. We tend to focus on destroying bad microbes. But taking care of good ones may be even more important.
Gut Feelings About Gastritis: When Your Stomach’s Sick
Your stomach lining has an important job. It makes acid and proteins that help break down the foods you eat. But when the lining gets inflamed—a condition called gastritis—it can cause long-term problems.
- Brain Cleaning System Discovered
- Bilingual Booklet on Sports Injuries
- Featured Website: ClinicalTrials.gov
ClinicalTrials.gov has launched a new beta version of its website, featuring a new integrated homepage and updated graphic design. In addition to the redesign, visitors will also have access to new and reorganized written content about clinical research, background information about the site, searching for studies, and maintaining study records. However, core functions of the site; including the basic and advanced search, search results options, and the study record data, will remain the same. The new site interface will run in parallel with the previous version for approximately four weeks after launch. After appropriate testing and additional minor changes it will permanently replace the previous interface in mid-September 2012.
ClinicalTrials.gov is the NLM-developed web-based registry and results database of clinical research studies. The website provides patients, clinicians, researchers, and the public with access to information about interventional and observational studies. As of August 2012, ClinicalTrials.gov contained over 130,000 clinical research studies in all fifty states and in 179 countries. Since it was launched in 2000, ClinicalTrials.gov has expanded in terms of scope, features, and intended audiences in response to the evolving policies and laws promoting the registration of clinical trials. For example, Congress enacted legislation in 2007 that added the first public results database. As a result, summary information about clinical trials of FDA-approved medical products would be freely available, whether or not the results were published in the medical literature. To accommodate the results database, new user interface features in ClinicalTrials.gov were launched in 2008, to display the results data tables and allow for searching of studies with results. Over time the Web site has featured the American Customer Satisfaction Index survey tool to collect feedback from users and usability evaluations have been conducted. The results of this user feedback, as well as the changing nature of the Web site, provided the motivation for redesigning ClinicalTrials.gov.
MLA Continuing Education credit is now available for our monthly Midday at the Oasis sessions! You need to register ahead of time in order to receive the credit. The usual place to register is linked on the Training and Exhibit Calendar or on the Midday listing. One hour of MLA CE credit will be awarded for the Midday sessions.
The July 18th talk is:
Presentation Title: ClinicalTrials.gov: Results Reporting, Unique Evidence, and Evolving Policy
Presenter: Stephen Kiyoi
Description: ClinicalTrials.gov, the second most heavily visited resource from the National Library of Medicine, now provides access to over 6,000 study results, many of which have not been published in the research literature. Learn more about recent and upcoming legislation governing results reporting, how to promote results reporting to clinical researchers at your institution, and how to search ClinicalTrials.gov as a unique source of evidence for systematic reviews.
Register and join us at 1-2PM (Pacific) | 10-11AM (Hawaii) | 1-2PM (Arizona) | 9-10AM (American Samoa) | 6-7AM Thursday (Guam) for Midday at the Oasis!
The Annual Meeting of the Medical Library Association (MLA) was held May 18-23, 2012 at the Washington State Convention Center in Seattle, WA. Attendees were invited to visit the NLM exhibit booth to meet NLM staff and see NLM Web products and services. The NLM Theater at the booth featured demonstrations and tutorials on a wide variety of topics. Recordings of the NLM Theater Presentations are now available:
- Disaster Health Information Update ( 27 min.)
- Drug, Toxicology & Environmental Health Update (20 min.)
- Everything You Ever Wanted to Know about ClinicalTrials.gov (14 min.)
- LinkOut and Submission Utility Update (8 min.)
- Managing Public Access Compliance Using My NCBI (27 min.)
- MedlinePlus and MedlinePlus Connect (23 min.)
- Native Voices and Other Voices (16 min.)
- NIHSeniorHealth Redesign (7 min.)
- Public Health & Health Services Research at NLM: A Tale of Two Portals (17 min.)
- PubMed Health (29 min.)
- PubMed Update (25 min.)
- UMLS and RxNorm Update (20 min.)
The National Institutes of Health has created a new web site, NIH Clinical Research Trials and You, to help people learn more about clinical trials, why they matter, and how to participate. Clinical trials are essential for identifying and understanding ways to prevent, diagnose, and treat disease. Research has shown that among the greatest challenges to recruitment of volunteers is the lack of general knowledge about what trials involve, where they are carried out, and who may participate.
Visitors to the web site will find information about:
•The basics of clinical trial participation
•First-hand experiences from actual clinical trial volunteers
•Explanations from researchers
•Links on how to search for a trial or enroll in a research matching program
In addition, health care professionals can read about evidence-based strategies for talking with patients about trials, print audience-tested posters to help promote trials in clinics and offices, and find other educational materials. NIH supports clinical research trials across the country and throughout the world. NIH’s ongoing effort to raise awareness about clinical research and educate potential participants about clinical trial options is vital to developing public support and understanding for how clinical research drives medical discovery and improves health outcomes.
With its December update, PubMed Health grows to over 18,000 systematic reviews and health technology assessments in the last ten years. With the inclusion of the Database of Reviews of Effects (DARE) from the Centre for Reviews and Dissemination in England, PubMed Health is getting close to comprehensive coverage of reliable systematic reviews on clinical effectiveness.
Other new features and content additions in this release include:
- Evidence-based, regularly updated information on cancer for consumers and health professionals from the National Cancer Institute (NCI) Physician Data Query (PDQ) database.
- Two full-text books under “Understanding research results” from the “Understand clinical effectiveness” tab:
- Irwig L, et al. Smart Health Choices: Making Sense of Health Advice. London: Hammersmith Press; 2008. Available from: http://www.ncbi.nlm.nih.gov/books/NBK63638/
- Evans I, et al. Testing Treatments: Better Research for Better Healthcare. 2nd edition. London: Pinter & Martin; 2011. Available from: http://www.ncbi.nlm.nih.gov/books/NBK66204/
- Simplified and broadened display of medical encyclopedia search results.
Clinical Alert: Commonly Used Three-drug Regimen for Idiopathic Pulmonary Fibrosis Found Harmful NIH Stops One Treatment Arm of Trial; Other Two Treatments to Continue
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, has stopped one arm of a three arm multi-center, clinical trial studying treatments for the lung-scarring disease idiopathic pulmonary fibrosis (IPF) for safety concerns. The trial found that people with IPF receiving a currently used triple-drug therapy consisting of prednisone, azathioprine, and N-acetylcysteine (NAC) had worse outcomes than those who received placebos or inactive substances.
The interim results from this study showed that compared to placebo, those assigned to triple therapy had greater mortality (11 percent versus 1 percent), more hospitalizations (29 percent versus 8 percent), and more serious adverse events (31 percent versus 9 percent) and also had no difference in lung function test changes. Participants randomly assigned to the triple- therapy arm also remained on their assigned treatment at a much lower rate (78 percent adherence versus 98 percent adherence).
The other two study arms, or intervention groups, of this IPF trial comparing NAC alone to placebo alone will continue. In stopping this part of the trial, the NHLBI accepted the recommendation of the Data and Safety Monitoring Board (DSMB) – an independent advisory group of experts in lung disease, biostatistics, medical ethics, and clinical trial design. The DSMB has been monitoring the study since it began.
Please visit the NLM website to read the entire clinical alert.